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It is my pleasure to give a talk for which no ques-
tion and answer period is allotted, containing infor-
mation based on opinion rather than data, and
scheduled for the last few hours of my presidency
from which precious little time will remain in which
to request my resignation. If only the world were
always this perfect. I began to think of a topic for
this address 2 years ago when I was named Presi-
dent-elect. Two months ago I received a phone call
that the program needed to be at the printer and my
title was required. Realizing that I had neither title
nor talk, I immediately responded, first to myself,
that “The Hour is Getting Late.” I then realized
that this address was scheduled right before lunch
and I was relieved that I could justify a brief talk and
simultaneously garner the approval of a hungry
audience by truncating the talk in deference to lunch
because “The Hour is Getting Late.” Then 2 weeks
ago I made the mistake of committing my thoughts
to text. In view of the dramatic challenges our
maturing profession now faces and the need for
introspection on the part of the profession as a
whole relating to our roles as clinicians, as
researchers, and as educators, the title in truth is
taken from Bob Dylan’s words in “All Along the
Watchtower”:
Let us not talk falsely now, 
The hour is getting late.
This is the last day of my Presidency of the 
Midwestern Vascular Surgical Society and I would
like to express to you my sincere gratitude for hav-
ing entrusted me and bestowed upon me this singu-
larly unique honor. Ours is a Society of which we
should all rightfully be proud. We have among our
membership a remarkable group of individuals
whose contributions to our profession have been
central to establishing the specialty of Vascular
Surgery as among the most scientifically challenging
and clinically rewarding in all of medicine. In rela-
tion to our past leaders, I feel humble. In relation to
our younger members and current trainees, I feel
proud.
However, as Bob Dylan also pointed out 35
years ago, “The Times They Are A Changin!”
External societal and governmental changes are
forcing a reevaluation of the role of clinicians in the
intellectual pursuits of research and education. I
sense that our profession is at a critical juncture.
The problem, however, is not precisely these exter-
nal pressures but rather may be our response to
them. Many of us chose to become vascular sur-
geons after being inspired by our leaders who
excelled not only as clinicians but as scientists and as
educators. In my own training at Columbia Presby-
terian, I was inspired by and I give thanks to John
B. Price, Jr. and Arthur Voorhees, Jr. whose intel-
lectual drive, academic prowess, and clinical dedica-
tion and abilities directly affected my selection of
vascular surgery as a career. Personally, I find the
clinical practice of vascular surgery tremendously
fulfilling and rewarding and could happily devote to
clinical practice all of my energies. Nonetheless, I
also find great satisfaction of a different type from
research and from teaching. Our recent and current
trainees are better prepared and more motivated
now to succeed in these intellectual pursuits than
was the case in the era in which I trained. However,
if our collective response to the current external
forces is to diminish our energies in academic activ-
ities, not only will the promise of our younger
members be unfulfilled, but our future leadership
may not serve as role models likely to encourage the
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best and the brightest among the next generation to
enter our field.
Come gather ‘round people 
Wherever you roam
And admit that the waters 
Around you have grown
And accept it that soon
You’ll be drenched to the bone.
If your time to you
Is worth savin’
Then you better start swimmin’
Or you’ll sink like a stone
For the times they are a-changin’.1
The changing times are not new but the extent
and the rapidity of change are new. James B. Wyn-
gaarden entitled his Presidential Address to the
Association of American Physicians “The Clinical
Investigator as an Endangered Species.”2 This
address was delivered in 1979. Also in 1979, David
Rogers, Professor of Medicine at Cornell University,
predicted:
Major teaching hospitals would begin to desert the
academic ship. The pressures for cost-containment would
cause them to make every effort to divest themselves of
medical school activities such as ongoing support of
research or ambulatory care programs for the poor…
Last, the pressures of practice would allow faculty less
time for teaching medical students, and the tensions
between those who generated income and those who were
involved in less time dependent, hence less reimbursable,
academic pursuits would steadily escalate.3
These predictions from 1979 are being reiterat-
ed by many today. Through a system of cross-subsi-
dization, our medical centers have relied on clinical
revenues to generate available funds to support our
faculties in research and in education, in terms of
grant support, in terms of protected time, and in
terms of income subsidization. Many of our depart-
mental and institutional leaders are predictably
responding to financial pressures by increasing the
clinical demands on their members often at the
expense of nurturing the academic potential of suc-
cessful and promising young surgical scientists and
educators.
Major developments in our understanding of the
pathophysiology of and therapeutic options for vas-
cular disease have historically come from those in
our own ranks. Alexis Carrell, Charles Guthrie,
Arthur Voorhees, Michael DeBakey, the list is long
and impressive indeed. However, many of the more
recent seminal advances in the field, which will dras-
tically change the care of vascular patients in the
future, for example, in arterial wall metabolism, in
gene therapy, in drug delivery, and in tissue engi-
neering, are products of well-funded laboratories of
nonsurgeons, of internists, and of basic scientists
with protected time. As a single admittedly difficult
to interpret data point, in FY96 the NIH awarded
643 investigator-initiated research grants, predomi-
nantly by the traditional RO1 mechanism, to faculty
members in departments of surgery, totaling
$162,565,809. By contrast, faculty of departments
of medicine received 3898 such grants totaling
$1,246,043,863. Data from the NIH is not available
specifically in reference to vascular surgery. It is my
impression that we in Vascular Surgery have more
than held our own as compared to the other surgical
disciplines. However, even in Vascular Surgery a
great deviation from this 7.5:1 ratio is unlikely.
Nonetheless, as vascular surgeons, we are fortu-
nate in two respects. It is my perception that our rel-
atively small group has retained a greater appreciation
for and excellence in research and education than is
the norm in most other surgical disciplines. This ori-
entation must be nurtured and our activities in these
areas redoubled. Secondly, our relatively small num-
bers should foster our ability to coordinate clinical,
research, and educational activity among our mem-
bers in an economic and intellectual cross-subsidiza-
tion, which ultimately is critical to the future of our
profession. The Lifeline Foundation is a clear exam-
ple of one such mechanism. Related to the future of
our profession and to your own individual futures, I
would like to encourage you all to attend this after-
noon’s panel discussion entitled “The Vascular Sur-
geon in the Next Millennium.”The four speakers,
Chris Haudenschild, Jim Stanley, Michael Reidy, and
Allan Callow, are among our most prescient innova-
tors in vascular biology. Each has spent a great deal of
effort building bridges to the future, each over some-
what different waters, and has promised an icono-
clastic preview of that future specifically as relates to
our activities as vascular surgeons.
Ambrose Bierce in 1911 defined “physician” as
“one upon whom we set our hopes when ill and our
dogs when well.”4 However, now even more than
usual are remarkable and frustrating times for all of
us in medicine. We grew up professionally in an era
of abundant resources, but the climate has dramati-
cally changed and resources are being constrained by
the transformation in the healthcare marketplace
spearheaded by managed care. Managed care,
threatening to many of our activities, however, is not
the basic problem but rather in a sense is the mes-
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senger. The underlying problem is the widening dis-
parity between the seemingly insatiable demands for
resources by the medical profession and the willing-
ness of society to supply these resources. Prior to
World War II, the research activities of our academ-
ic medical centers were small and were funded for
the most part by foundations and by industry rather
than by the federal government. During World War
II, the government invested heavily in university lab-
oratories in support of the war effort, with great suc-
cess. This successful approach led the federal gov-
ernment to decide to heavily invest public funds into
science and science education resulting in a huge
expansion of the academic medical center. The next
major transformation occurred in the 1960s with the
enactment of the Medicare/Medicaid legislation.
This resulted in the confluence of two enormous
and steadily growing streams of federal support for
our medical centers, clinical reimbursement for care
provided to targeted patient populations, and direct
support of research laboratories, resulting in the
development of cross-subsidization mechanisms
supporting research, education, and clinical activi-
ties. In 1994 only 19% of the $27.5 billion expend-
ed by our 126 medical schools derived from federal
research funds, predominantly from the NIH, while
49% derived from clinical practice revenues. State
and local government funds, previously accounting
for 20% of medical school revenues, have fallen to
11%. The dependence of our institutions on clinical
revenues is obvious and the impact of managed care
on these revenues is creating an unstable situation. It
demands of clinicians an increasing commitment to
clinical activity. Despite the sustained allocations for
research by the NIH, competition for these awards
is also increasing dramatically. These conditions have
led to an environment not supportive of academic
activity by any but the most driven of our young fac-
ulty and a dangerous dichotomization of faculty into
either clinical or research areas.
In 1995 the co-chair of the President’s Com-
mittee of Advisors on Science and Technology
(PCAST) wrote to President Clinton that”academic
health centers are beginning to show signs of serious
stress” and that financial pressures “could have a
devastating impact on the nation’s capacity to sup-
port medical research and education.”5 It is incum-
bent upon us as a profession to develop systems by
which to maintain the interwoven fabric of research,
education, and clinical care upon which the future of
our profession and the development of therapeutic
options for our vascular patients depends.
A study published in July 1997 in JAMA evalu-
ated the effects of market competition on the activi-
ties and attitudes of clinical faculty in medical
schools (Fig. 1).6 Faculty in medical schools located
in areas with higher managed care penetration pub-
lished significantly fewer scientific articles, reported
significantly greater patient care responsibilities and
perceived lower levels of departmental cooperation
and higher levels of conflict. Also published in the
July 1997 issue of JAMA was a companion paper
comparing the effects of managed care penetration
on the numbers and dollar amounts of NIH awards
(Fig. 2).7 Medical schools geographically located in
areas of higher penetration fared significantly worse,
the difference amounting to $98,000,000 in 1995
and could be directly attributed, not surprisingly, to
a difference in awards to clinical rather than basic
science departments. Although these findings are
not unexpected, they are extremely troublesome. A
diminution in basic and clinical research will have a
potentially huge negative impact on clinical advance-
ments. Our trainees will perceive the professional
dissatisfaction of our faculty and elect other career
options. We as a small professional group must sup-
port the opportunities for motivated and capable
young trainees and faculty to pursue their academic
ambitions for which we so carefully prepare them.
The hour is getting late.
In 1994 the Institute of Medicine charged a sub-
committee consisting of Clyde Barker, Samuel Wells,
and James Thompson and chaired by Haile Debas to
evaluate the status of surgical research. The conclu-
sion was that “surgery, perhaps more than any other
clinical discipline, needed to increase its research….
Research in surgery was considered to be inadequate
in both scope and quality.”8
Certainly, a good deal of very excellent basic and
clinical research is being performed by surgeons in
general and by vascular surgeons in particular. How-
ever, are we doing enough? If not, what are the
obstacles that must be overcome in order to recruit
research oriented trainees into vascular surgery, to
optimally train and motivate them toward academic
activity, and to create a professional environment in
which such well-trained and motivated young facul-
ty are allowed to fulfill their promise and thus
strengthen the future of our profession?
I would argue that a solution to the last of these
points, i.e., the establishment of an academically
supportive environment, whichnurtures the produc-
tivity of our faculty, will go far toward solving the
first two points. A productive and contented faculty
member produces not only the direct rewards of his
or her own research, but serves more importantly as
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a role model to induce our junior academically ori-
ented medical students to consider embarking on a
career in vascular surgery. This select cadre of stu-
dents will likely seek out and develop the appropri-
ate training and skills to pursue meaningful basic and
clinical research in vascular surgery and be more
competitive for procuring extramural funding,
which in turn will lengthen their academic half-life as
surgeon scientists and thus close the cycle by opti-
mizing the academic role model characteristics for
the next generation of recruitment.
As vascular surgeons, we are at a disadvantage in
recruiting the best and the brightest among our stu-
dents. The curriculum at most of our medical
schools is such that in the first 2 years medical stu-
dents are exposed primarily to the faculty and the
laboratories of the basic scientists. Even among clin-
icians, participation in educational programs during
these 2 years is greater by internists, whose time is
often more flexible, than by surgeons. During the
third and fourth years of medical school, exposure to
research laboratories headed by faculty of nonsurgi-
cal departments is also greater, in part a function of
the time commitments of busy surgeons and in part
simply a function of numbers. We can do better. For
example, it has been my experience that our basic
science departments are very enthusiastic to include
surgeons as visiting lecturers to discuss their own
research in areas related to the topic being taught
and to provide insights into the clinical relevance of
that particular field of science.
The costs of medical education are escalating and
our trainees often enter practice with heavy financial
debts. Surgical training, particularly in a subspecial-
ty such as ours, is long and junior attendings often
feel a financial need to devote their energies into the
more remunerative activities of clinical practice. The
economic disparity between clinical practice and aca-
demic activity is a major and continuing disincentive.
The recent transformation of the healthcare market-
place has inadvertently reduced this disparity. 
However, in the face of retracted clinical revenues
entering our departments and institutions from
practice plan arrangements, many of our department
chairpeople are responding by placing yet greater
clinical demands on our research oriented faculty.
The long-term effects of such shortsighted policies
are not clear but are unlikely to be supportive of aca-
demic productivity and professional satisfaction. We
must argue strongly against such policies, while at
the same time developing alternate sources of sup-
port. One such mechanism, I believe, is the Lifeline
Foundation, which is currently maturing and
expanding by integrating financial infusions from
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Fig. 1. Reproduced from Campbell EG, et al., JAMA 1997;278:222-6 with permission of
The American Medical Association.
the generous donations that we as a Society and 67
of us as individuals have made with additional and
synergistic funding from the NIH and from indus-
try. I strongly encourage your continued and
increasing support for this Foundation, which is
becoming progressively more able to directly
enhance the training and the research programs of
our vascular surgical community.
The shear volume and depth of scientific knowl-
edge is increasing at a remarkable rate and the req-
uisite techniques for successful state of the art scien-
tific investigations are becoming more complex. We
can no longer consider dabbling in science to be
appropriate. As clinicians we must be integrative in
our thinking regarding care for the total patient and
as such we need to actively pursue the integrative
research strategies of outcomes analysis and careful
unbiased evaluation of emerging technologies.
However, scientific progress has dramatically shifted
from the integrative to the reductionist. To remain a
dynamic profession, a subset of our trainees must be
schooled in the sophisticated reductionist method-
ologies needed to explore pathophysiologic and
therapeutic concepts at the cellular and molecular
levels. Many of our vascular surgical fellowships
include a dedicated year of research. I am extremely
impressed by the investigative potential and com-
mitment of our graduates. However, this single year
of research training is often insufficient to establish
our trainees as successful independent investigators.
The training opportunities must begin earlier.
Numerous opportunities exist to support the
training of our students, house staff, and young fac-
ulty members interested in basic and clinical research
careers, including support mechanisms of the NIH,
the VA, and foundations, including the Howard
Hughes and the Lifeline Foundations. We must
encourage applications for such training support by
current and future vascular surgeons.
The NIH has established an array of training and
career development awards, some designed specifi-
cally for clinical investigators. As a whole success
rates in competing for these awards has been approx-
imately equal between MDs and PhDs, for example,
48% ± 6% for MDs versus 44% ± 8% for PhDs com-
peting for F32 awards in the years 1980 to 1988.
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Fig. 2. Reproduced from Moy E et al., JAMA 1997;278:217-21 with permission of The
American Medical Association.
However, the number of applications by physicians
has been decreasing during the past decade so that
the number of awards to PhDs now exceeds those to
MDs by fourfold despite the fivefold greater num-
bers of MDs in our academic centers. Still more dis-
concerting, if one looks directly at NIH training
grants awarded to departments of medicine versus
surgery in FY96, medical departments nationally
received 323 training grant awards compared to
only 43 to departments of surgery, an eightfold dif-
ference. We as surgeons are either not attracting into
our field those likely to seek out such research train-
ing or are not supporting their development and
encouraging their competition for such training. We
have a good number of superb laboratories and
mentors among our vascular surgical community,
which should be conducive to the successful training
of students and fellows awarded these training
grants. We must stimulate our trainees to apply and
allow them the time and resources to succeed. I am
happy to report that the Lifeline Foundation and the
NHLBI are currently finalizing details of a program
designed to award K08 fellowships of 3 to 5 years of
support to be awarded specifically to vascular sur-
geons with deserving applications, with funds
derived jointly from Lifeline and the NIH.
Why is this so important? The likelihood of suc-
cessful competition for investigator initiated awards
by the NIH, the traditional RO1 awards, can be
directly linked to the applicant’s prior training
opportunities. In the most recent data I could find,
recipients of F32 training grants between 1976 and
1986 had an eventual 37.8% likelihood of success-
fully competing for RO1 grants following their
training, considerably greater than the overall award
rate, and approximately equal comparing MDs to
PhDs.9
It is my impression that in relation to its size vas-
cular surgery has been far more cognizant of these
issues than many other clinical disciplines, and has
been more successful in recruiting and training
future researchers and educators. The most success-
ful and motivated among this group are entering our
faculties with the expertise and the ambition to be
successful clinicians, researchers, and teachers. Let’s
examine the obstacles they may then encounter.
In the most common scenario this individual
entering practice is expected and appropriately
desires to utilize his or her clinical training to estab-
lish an active clinical practice. He or she is similarly
motivated and nominally encouraged to establish an
active research program with the goal of developing
independent grant support. It is incorrect to consid-
er either activity as part time. Patient recruitment
often depends, perhaps unnecessarily, on competi-
tion with other clinicians devoting their full atten-
tion to clinical activity and who may be incorrectly
perceived to be either more interested in or more
capable of clinical pursuits. Success in procuring
extramural research funding depends on his or her
grant application competing against those submitted
by scientists devoting their full energies toward
research with more opportunity to develop prelimi-
nary data, to write the application itself, and to
devote to the proposed studies if they are funded. It
is no wonder that the academic half-life of our facul-
ty is decreasing. When expressed as time required for
50% of first time NIH grant award winners to ter-
minate research activity, in 1955 it was 12.9 years
and in 1978 it was 5.6 years. The rate in 1994 has
been estimated to be in the low fives.10 This data
reflects all NIH awardees and similar data specific to
surgeons is not available. Given the increasing clini-
cal demands, I would expect the figures among sur-
geons to be still worse.
I do not believe that the biggest problem is the
availability of extramural funds or the quality of the
applications submitted by the few who are trained
and motivated to prepare them. The success rate in
FY95 for NIH research support of submissions from
departments of surgery was 24.5 as compared to an
overall rate of 27.4. Both figures may sound high
but are so because both training and investigator ini-
tiated awards are included. Bernadine Healy, the
recent Director of the NIH, wrote in the New Eng-
land Journal of Medicine that physician scientists
may have become an endangered species, using Dr.
Wyngaarden’s term, not because they fail to succeed
but because they fail to compete.11 I believe this is
true and the current trends are intensifying this
problem.
NIH funding is unquestionably more competi-
tive than ever before but the dollars awarded and
number of grants funded have not fallen. In fact,
despite the current enthusiasm by the government
for budget cutting, the NIH has received strong
congressional support with small but important
budgetary increases of roughly 4% to 5% per annum.
However, the rate of increase has declined. In 1995,
although the clinical faculty in United States medical
schools outnumbered the basic science faculty by
fivefold, NIH grant awards were made to 4726
PhDs and only 1489 MDs plus 390 holders of joint
degrees. Success rates of applications were very sim-
ilar among these groups. The preponderance of
awards to PhDs is a direct result of differences in
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numbers of applications submitted. The number of
applications, however, submitted by surgeons is
diminishing. As most of you know, the peer review
process used by the NIH distributes all applications
to study sections whose membership is considered to
include the necessary expertise to review grants
relating to particular areas of investigation. It may
come as a surprise to you, however, that of the 2434
study section members in all of NIH’s permanent
study sections, only 21 are surgeons. That is all sur-
geons, not just vascular surgeons. I have heard the
argument that we need more surgical representation
on the study sections to increase the success rate of
our applications. Personally, I am not convinced that
this is actually relevant. However, having served on
one of these study sections for 4+ years, I do appre-
ciate the immense amount of time required. If we
feel it important to increase surgical representation
on the study sections, are we and are our local
administrators prepared to facilitate the availability
of this time for the reviewer, time which is not
directly supportive of the need of our institutions for
clinical revenues? And expand this concept further.
Are we and are our local administrators prepared to
facilitate the availability of time for the recipients of
these highly competitive and prestigious awards to
successfully pursue and complete their funded
research, often extremely time intensive and not
directly remunerative to departmental coffers?
Industrial support for research during the past
decade has grown from 31% to 48% of the total
research expenditures (Fig. 3). Industry support for
research and development has grown 13.6% annual-
ly over the last decade. Much of this research is ori-
ented toward product development. Recent changes
in the tax codes and in technology transfer arrange-
ments have led to a large shift by pharmaceutical,
biotechnology, and medical device companies away
from “in house” research in favor of industry-spon-
sored research programs based in our medical insti-
tutions. Recently, a progressively larger proportion
of this research support has gone to the clinical staff
of nonacademic institutions. We can and must all
contribute. We as vascular surgeons are uniquely
positioned to spearhead much of this research relat-
ed to therapeutic modalities for treating vascular dis-
ease both in the laboratory in the preclinical phases
and, when appropriate, in our patient population.
These investigations must be performed in accor-
dance with the highest standards of medical ethics
and scientific integrity. The development of novel
medical devices requires innovation, commitment,
and scientific sophistication all of which we as a pro-
fessional community possess. However, preclinical
studies require investigator time, and clinical testing
of these devices is not generally compatible with the
current drive toward cost-containment, offering
established therapies at the minimum cost. The
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Fig. 3. Reproduced from Moy E et al., JAMA 1997;278:217-21 with permission of The
American Medical Association.
unfortunate long-term effect of managed care will
likely be a slow-down in the time required to bring
new technologies to clinical application. Nonethe-
less, new technologies will continue to develop and
we as vascular surgeons must not abrogate our inves-
tigative responsibilities and allow these technologies
to develop in the hands of others perhaps less knowl-
edgeable and expert in the treatment of our patients.
Developments in catheter-based interventions are an
obvious case in point. We argue appropriately that
our expertise makes us the most qualified to utilize
these new techniques but I believe we would be less
challenged by the interventional radiologists and
cardiologists had we been more involved in the early
research and development phases of these technolo-
gies in the first place.
The area of greatest threat to our research pro-
ductivity, however, derives from the diminishing
availability of clinical revenues by which medical
institutions have traditionally cross-subsidized
research and educational activities. When one com-
pares the relative contribution of clinical revenues to
the funds awarded to our medical schools in 1980 to
1981 versus 1993 to 1994, the problem is obvious
(Table I). These revenues have increased from 21.9%
to 46.5% of total available funds. Although total
grants and contracts increased fourfold during that
period, the relative contribution of this funding
source actually decreased from 44.1% to 30.6% of
total revenue.12 A major beneficiary of our faculty
practice plans has been research at a level estimated
in 1996 to be $815 million nationally (Fig. 4).
These clinical revenues similarly support undergrad-
uate medical education at $702 million and gradu-
ate medical education at $594 million. Unreim-
bursed teaching by volunteer faculty contributed an
additional $545 million.13 As the healthcare market-
place diminishes, our reimbursement rates in gener-
al and specifically eliminates direct subsidies for clin-
ical research and for education, these revenues are
rapidly decreasing. Volunteer faculty are less willing
to participate in teaching programs. Personal
income concerns as well as shifts in departmental
priorities lead many academically productive sur-
geon-scientists to move progressively toward the
clinics, as is reflected by the diminishing academic
half-life of our faculty. Much of the clinical research
and to a lesser degree basic research of our faculty
has been subsidized by a steadily diminishing pool of
intramural funds. In a recent study published in the
Southern Medical Journal,14 74% of articles pub-
lished in the surgical journals were based on these
nominally “unfunded” projects, a percentage greater
than those published by internists or pathologists.
As surgeons, our clinical expertise is tremendously
rewarding financially to our institutions, which are
demanding of us still greater clinical loads. Yet the
decreasing clinical revenues are likely to have a dis-
proportionately negative impact on the intramural
funding of our own research programs. Without
these sources of research support and the availability
of protected time, the well-trained new members of
our vascular surgery faculties will find it still more
difficult to develop adequate preliminary data on
which to base applications for extramural support.
Academic productivity will decrease, professional
satisfaction will decline and the next generation of
the best and the brightest of our students will more
likely find their academic role models elsewhere. We
must support ourselves.
Let’s consider the possibilities. We can opt to sim-
ply terminate research by surgeons. This approach is
extraordinarily penny-wise and dollar-foolish but has,
in essence, been chosen by many of our depart-
ments.8 Not only would this approach directly
diminish and potentially end the future role of vascu-
lar surgeons in the care of our patients but is a grave
disservice to the group of superbly trained and moti-
vated vascular surgeons recently completing and
soon to complete our fellowship programs.
A second option is to recruit research dedicated
PhDs into our divisions of vascular surgery and to
delegate research programs to them. Certainly, there
is a very real value to this option and it has worked
in some of our programs. Currently, 10.7% of all fac-
ulty positions in departments of surgery nationally
are held by PhDs. The recruitment of top quality
PhDs into clinical departments, however, is often
difficult. Clinical departments have traditionally
been less than optimally responsive to their needs,
less willing to assign to PhDs administrative deci-
sion-making roles, and less likely to facilitate their
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Fig. 4. Reproduced with permission from Jones RE,
Sanderson SC, Acad Med 1996;71:299-307.
professional growth within their areas of expertise
and training. Although the inclusion of high quality
PhDs within our divisions is desirable for many rea-
sons, research and research training should not be
totally relegated to this group, many of whom may
have little clinical insight and who are not capable of
independently carrying out basic or applied patient
oriented research, which must necessarily involve
MDs as participants.
A third option is to establish interdisciplinary
collaborations between vascular surgeons and basic
scientists with overlapping interests. This approach
should be nourished wherever possible. The basic
scientists in some instances should be provided joint
appointments in surgery and become involved in the
training of our residents and vascular fellows. How-
ever, for the collaborations to succeed, the vascular
surgeon must bring to the table both a needed
expertise and the available time to devote to the col-
laboration. Among our groups, we clearly have the
former. It is the available time that is progressively
more suspect.
A fourth option is to establish a two-tiered sys-
tem among our faculty such that one group is fully
clinically oriented and the other is research oriented.
However, I still strongly believe that the concept of
the triple threat is not dead. We do have among us
and continue to train individuals capable of success
in clinical practice as well as in research and educa-
tion. If we do not believe that, I would argue that
the research year of our 2-year fellowships should be
summarily and immediately abandoned. To train
individuals to succeed in both arenas, we are oblig-
ated to provide them the opportunity to succeed.
The artificial segregation of faculty members into
either clinical or research divisions necessarily raises
the issues of equality of promotion and of reward
and the potential for deterioration of the program
resulting from perceived inequalities. Surely, an arti-
ficial segregation is also likely to diminish the pro-
fessional satisfaction of faculty trained and interested
in pursuing those activities from which he or she has
been excluded. The cycle concludes of course by the
long-term effects of this change on our recruitment
of the best and brightest into vascular surgery in the
future.
The fifth and last option is to create professional
environments in which those who have selected to
train in and to enter our field and who have secured
adequate training in both research techniques and in
clinical practice are afforded the opportunity to suc-
ceed in both. This cadre of ambitious new vascular
surgeons must be provided the necessary resources
in the form of research space, start up funding, and
potential collaborators, in the form of opportunities
for patient accrual, and in the form of protected time
without an inordinately negative impact on personal
remuneration. It is precisely on this that the very
future of our profession depends.
The chairman of one of our most prominent
departments of surgery wrote in 1995 that the most
attractive solution to achieving this option would be
for all faculty members to accept shrinking personal
income to maintain the cross-subsidization of
research and education through clinical revenues.8
He added in the next sentence, however, that such a
proposal would likely receive little enthusiasm from
his faculty. My guess is that his faculty would soon
become someone else’s faculty.
It is my contention that we have not made the
most of our opportunities. We can and should be
more involved in the teaching of beginning medical
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Table I. Medical school funding sources, millions of dollars, 1980-1981 and 1993-1994
1980-1981 1993-1994
Percent Percent
Amount of total Amount of total
Clinical revenues $1,424 21.9% $12,779 46.5%
Practice plans 1,020 15.7 9,120 33.2
Payments from hospitals 404 6.2 3,659 13.3
Other operating revenues 2,197 33.9 6,319 23.0
Federal appropriations 57 0.9 110 0.4
State appropriations 1,351 20.8 2,781 10.1
Tuition and fees 348 5.4 1,130 4.1
Other 441 6.8 2,298 8.4
Grants and contracts* 2,861 44.1 8,411 30.6
Total $6,482 100.0% $27,509 100.0%
SOURCE: Association of American Medical Colleges, Liaison Committee on Medical Education (LCME) Questionnaire.12
*Including indirect cost recovery.
students and encourage both them as well as under-
graduates to participate in our clinical and basic
research projects. Those who show an early inclina-
tion to pursue a career in vascular surgery should be
carefully mentored by us as role models and encour-
aged to seek out clinical or basic research training.
The graduates of our vascular fellowships should be
afforded the opportunity to succeed in all areas in
which they have developed adequate training and
motivation. The provision of such opportunity will
certainly allow some among this group to success-
fully compete for funding. Important as well is our
involvement in self-evaluation, the trendy buzzword
for which is “outcomes research.”
Industrial support is available and we as vascular
surgeons need to be intimately involved in early
phases of medical device and biotechnology research
and development if we are to remain the cornerstone
among those caring for patients with vascular dis-
ease. We must develop in our departments and divi-
sions incentive plans to encourage our junior faculty
to engage actively in surgical research. No one can
afford to dabble. Novel creative proposals are being
developed, some of which deserve our support. Ken-
neth Shine, President of the Institute of Medicine,
has proposed 1% assessment on all healthcare premi-
ums to support clinical research and to be imple-
mented over a 4-year period.15 Considering that the
1995 total healthcare expenditures amounted to
$988 billion, such an assessment would certainly
benefit progress in clinical research on behalf of our
current and future patients. We must continue to
provide our extraordinary and unassailable clinical
expertise in all facets of care of our patients with vas-
cular disease and continue to extend this care to all
such patients regardless of the constraints imposed
by their insurance status and their economic reali-
ties. We must continue to support and expand our
level of support for the Lifeline Foundation, one
novel mechanism which we actually do control and
by which we can promote the training and academ-
ic opportunity for our vascular surgery colleagues.
We must continue to serve as role models for the
most junior of our students so that the best and the
brightest among them choose to devote their train-
ing and their careers to vascular surgery. And we
must do this soon.
The hour is getting late.
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